Proteins and Peptides
10 September 2014
European Commission grants Lilly and Boehringer Ingelheim’s insulin glargine product marketing authorisation in Europe10 September 2014
EMD Serono Presents New Data on Rebif ® (Interferon beta-1a) and Multiple Sclerosis Pipeline at Joint ACTRIMS-ECTRIMS Meeting in Boston9 September 2014
Mimetogen Pharmaceuticals Announces Topline Results of Its Second Clinical Study with MIM-D3 for the Treatment of Dry Eye Syndrome9 September 2014
C3 Jian Completes Phase 2 Clinical Trial of Anti-Cavity Drug8 September 2014
Synthetic Biologics Highlights New Data from C. difficile Program Presented at the 54th ICAAC4 September 2014
Lilly’s Basal Insulin Peglispro Demonstrated HbA1c Superiority against Lantus® in Phase III Trials in Patients with Type 1 Diabetes3 September 2014
Ultragenyx Announces Positive Interim Data From Phase 1/2 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis 73 September 2014
Capstone Therapeutics Announces Phase 1a Results for AEM-28 Showing Safety and Biomarker Efficacy Signals3 September 2014
Sophiris Bio Reports Completion of Enrollment in the “PLUS-1” Phase 3 Trial of PRX302 for Benign Prostatic Hyperplasia1 September 2014
Ipsen Announces Acceptance of Filings for Somatuline® in the Treatment of GEP-NET1s in the US with Priority Review and in Europe25 August 2014
La Jolla Pharmaceutical Company Announces First Patient Enrolled in Clinical Trial of LJPC-501 in Hepatorenal Syndrome21 August 2014
Auxilium Pharmaceuticals, Inc. Announces Positive Data From Phase 2a Study Of CCH In Patients With Cellulite19 August 2014
FDA Grants Tentative Approval for Lilly and Boehringer Ingelheim’s Basaglar™ (insulin glargine injection)18 August 2014
Expression Therapeutics LLC Selects ABL, Inc. to Support Cell Line Development for Hemophilia A Factor VIII Infusion Therapy17 August 2014
Biogen Idec’s PLEGRIDY™(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis12 August 2014
Xenetic Biosciences Announces Ongoing Safety and Efficacy Data From Phase 2 Trial of ErepoXen(R)News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports